Mesh Bio Co-Founders Andrew Wu and Arsen Batagov
Singapore-based chronic disease management startup Mesh Bio has raised US$3.5 million in Series A financing led by East Ventures.
Elev8, Seed Capital, and other existing shareholders also co-invested.
The funding will allow Mesh Bio to offer its digital twin technologies to healthcare providers and scale the deployment of these solutions across Hong Kong and Southeast Asia, mainly Indonesia and the Philippines.
Also Read: Mesh Bio raises US$1.8M seed to help doctors predict diseases before they occur
Dr. Andrew Wu, Co-Founder and CEO of Mesh Bio, said: “Southeast Asia presents myriad unmet healthcare needs, and our focus is to address these gaps effectively.”
The high prevalence of chronic diseases, from diabetes to heart disease, in Southeast Asia has pushed more general practitioners who lack specialist training in endocrinology to manage patients with chronic diseases.
Founded in 2018 by Wu and Arsen Batagov (CTO), Mesh Bio delivers digital solutions to help healthcare providers with patient management. Its solutions offer patient data and predictive analytics that equip doctors with information and intelligence about their patients and the diseases they live with.
The company develops clinical decision support analytics and automation solutions for managing chronic diseases such as cardiovascular disease. Its DARA Health Intelligence Platform enables data-driven care delivery, which improves patient engagement and health outcomes. It has been used by more than 120 medical centres across Singapore, Malaysia, and Indonesia for preventive health screening.
Also Read: WhiteCoat closes a tranche of Series B round, poised to break even in Singapore
This new investment comes three months after the startup received approval from Singapore’s Health Sciences Authority (HSA) to market its HealthVector Diabetes as a Software Medical Device (SaMD). A chronic disease management solution, HealthVector Diabetes is currently used in an implementation pilot at Singapore General Hospital (SGH), Tan Tock Seng Hospital (TTSH), and selected polyclinics for potential clinical adoption.
Mesh Bio previously raised a US$1.8 million seed funding round in October 2021.
—
X marks Echelon. Join us at Singapore EXPO on May 15-16 for the 10th edition of Asia’s leading tech and startup conference. Enjoy 2 days of building connections with potential investors, partners, and customers, exploring innovation, and sharing insights with 8,000+ key decision-makers of Asia’s tech ecosystem. Get your tickets here.
Want more from your Echelon experience? Be an Echelon X sponsor or exhibitor. Send enquiry here.
The post Chronic disease management startup Mesh Bio bags US$3.5M Series A appeared first on e27.